{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T09:49:30Z","timestamp":1648633770129},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1016\/j.lungcan.2007.12.002","type":"journal-article","created":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T05:10:22Z","timestamp":1214629822000},"page":"67-72","source":"Crossref","is-referenced-by-count":10,"title":["The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients"],"prefix":"10.1016","volume":"61","clinical-trial-number":[{"clinical-trial-number":"nct00330746","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00401492","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Cesare","family":"Gridelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ermelinda","family":"De Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santi","family":"Barbera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirella","family":"Sannicol\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FrancoVito","family":"Piantedosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Brancaccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Maione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Renda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Signoriello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2007.12.002_bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(01)00486-7","article-title":"Global cancer statistics in the year 2000","volume":"2","author":"Parkin","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2007.12.002_bib2","unstructured":"SEER Cancer Statistics review 1975\u20132004. http:\/\/www.seer.cancer.gov."},{"key":"10.1016\/j.lungcan.2007.12.002_bib3","doi-asserted-by":"crossref","unstructured":"The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999;91:66\u201372.","DOI":"10.1093\/jnci\/91.1.66"},{"key":"10.1016\/j.lungcan.2007.12.002_bib4","first-page":"890","article-title":"Gemcitabine in the treatment of non-small cell lung cancer for elderly patients","volume":"26","author":"Furuse","year":"1999","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.lungcan.2007.12.002_bib5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0169-5002(99)00098-7","article-title":"Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer. A multicentre phase II study.","volume":"27","author":"Ricci","year":"2000","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2007.12.002_bib6","first-page":"3675","article-title":"Gemcitabine as single agent in the treatment of elderly patients with advanced non-small cell lung cancer","volume":"20","author":"Altavilla","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/j.lungcan.2007.12.002_bib7","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/00000421-200112000-00018","article-title":"Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB\/IV non-small-cell lung cancer","volume":"24","author":"Martoni","year":"2001","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.12.002_bib8","first-page":"3053","article-title":"Gemcitabine as single agent chemotherapy in elderly patients with stages III\u2013IV non-small cell lung cancer (NSCLC): a phase II study","volume":"22","author":"Bianco","year":"2002","journal-title":"Anticancer Res"},{"key":"10.1016\/j.lungcan.2007.12.002_bib9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/jnci\/95.5.362","article-title":"Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial","volume":"95","author":"Gridelli","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lungcan.2007.12.002_bib10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/JCO.2004.09.053","article-title":"American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003","volume":"22","author":"Pfister","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.12.002_bib11","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1200\/JCO.2005.00.224","article-title":"Treatment of advanced non-small-cell lung cancer in the elderly: results of an International Expert Panel","volume":"23","author":"Gridelli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.12.002_bib12","first-page":"6823","article-title":"Pharmacologically directed design of the dose rate and schedule of 2\u2032. 2\u2032-difluorodeoxycytidine (gemcitabine) administration in leukaemia","volume":"50","author":"Grunewald","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2007.12.002_bib13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","article-title":"A phase I clinical, plasma and cellular pharmacology study of gemcitabine","volume":"9","author":"Abbruzzese","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.12.002_bib14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.1992.10.3.406","article-title":"Gemcitabine in leukemia: a phase I clinical, plasma and cellular pharmacology study","volume":"10","author":"Grunewald","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.12.002_bib15","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1200\/JCO.2003.09.140","article-title":"Randomized phase II comparison of dose intense gemcitabine: thirty-minute infusion and fixed dose rate infusion inpatients with pancreatic adenocarcinoma","volume":"21","author":"Tempero","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.12.002_bib16","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1200\/JCO.2007.12.5708","article-title":"Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non-small cell lung cancer: the MILES-2P studies","volume":"25","author":"Gridelli","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2007.12.002_bib17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/cncr.11501","article-title":"Prolonged gemcitabine infusion in advanced non-small cell lung cancer carcinoma","volume":"98","author":"Ceribelli","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2007.12.002_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.lungcan.2005.10.013","article-title":"Prolonged gemcitabine infusion in advanced non-small-cell lung cancer with stable disease after gemcitabine 30-min infusion","volume":"51","author":"Tibaldi","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2007.12.002_bib19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.lungcan.2006.03.004","article-title":"A randomized phase II trial evaluating standard (50mg\/min) versus low (10mg\/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy","volume":"52","author":"Cappuzzo","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2007.12.002_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-006-0237-2","article-title":"Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer","volume":"59","author":"Xu","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.lungcan.2007.12.002_bib21","doi-asserted-by":"crossref","first-page":"v142","DOI":"10.1093\/annonc\/mdj970","article-title":"Pharmacokinetic evaluation of gemcitabine and 2\u2032. 2\u2032-difluorodeoxycytidine-5\u2032-triphosphate after prolonged infusion in patients affected by different solid tumors","volume":"17","author":"Cattel","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2007.12.002_bib22","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1470-2045(07)70146-8","article-title":"Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study","volume":"8","author":"Gridelli","year":"2007","journal-title":"Lancet Oncol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950020700685X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950020700685X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T07:09:04Z","timestamp":1557644944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950020700685X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S016950020700685X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2007.12.002","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}